PET-CT scans could sharpen radiation targeting for liver tumors

NCT ID NCT02088775

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study investigates whether PET-CT scans can accurately measure the radiation dose delivered by radioactive spheres during a liver cancer treatment called radioembolization. Researchers will compare scans taken before and after the procedure in patients with liver tumors. The goal is to see if this imaging method can help doctors plan more effective and safer radiation doses in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

radioactive spheres (SIR-Spheres or TheraSphere)

What this could lead to

If successful, this approach could help doctors plan more precise radiation doses for liver cancer, potentially improving tumor control while reducing side effects.

What could go wrong

This is an observational registry study, not a treatment trial. It may not lead to changes in practice, and results may vary by tumor type or sphere type.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult hepatocellular carcinoma bile duct neoplasm biliary tract cancer cancer extrahepatic bile duct carcinoma hepatocellular carcinoma malignant tumor of extrahepatic bile duct

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States